Some Boston public school students are spending their summer vacations learning and working at a global biotech company.

A potentially billion-dollar acquisition of Gilgamesh Pharmaceuticals suggested big pharma may finally be willing to place ...

Frazier was among the most active venture investors in 2024, according to analysts at William Blair, backing 17 private life ...

Vertex Pharmaceuticals (VRTX) wrapped up July with a modest 0.16% uptick, signaling a cautious optimism in the stock market.

U.S. equities rebounded strongly in Q2, with growth stocks and mid-caps leading gains; our portfolio outperformed via IT, ...

Franklin Templeton shares Q2 2025 results for ClearBridge All Cap Growth Portfolios: tech wins offset health care drag. See ...

Vertex Pharmaceuticals is making waves, popping up as one of the most searched stocks. Should you jump on the bandwagon?

AbbVie, Bristol Myers Squibb and Eli Lilly appear “relatively well-positioned,” while Novartis and Roche look more at risk, ...

This was the stock's third consecutive day of losses.

The market expects Vertex Pharmaceuticals (VRTX) to deliver a year-over-year increase in earnings on higher revenues when it ...

Third, Vertex still has an exciting pipeline in CF and elsewhere. For instance, the company's late-stage candidate for APOL-1 ...

Vertex Pharmaceuticals trades at $469.50 and has moved in lockstep with the market. Its shares have returned 6.5% over the ...